MINT-CITALOPRAM TABLET

Land: Kanada

Tungumál: enska

Heimild: Health Canada

Virkt innihaldsefni:

CITALOPRAM (CITALOPRAM HYDROBROMIDE)

Fáanlegur frá:

MINT PHARMACEUTICALS INC

ATC númer:

N06AB04

INN (Alþjóðlegt nafn):

CITALOPRAM

Skammtar:

20MG

Lyfjaform:

TABLET

Samsetning:

CITALOPRAM (CITALOPRAM HYDROBROMIDE) 20MG

Stjórnsýsluleið:

ORAL

Einingar í pakka:

30/100/500

Gerð lyfseðils:

Prescription

Lækningarsvæði:

SELECTIVE-SEROTONIN REUPTAKE INHIBITORS

Vörulýsing:

Active ingredient group (AIG) number: 0136243001; AHFS:

Leyfisstaða:

APPROVED

Leyfisdagur:

2014-09-05

Vara einkenni

_MINT-CITALOPRAM Product Monograph_
Page 1 of 45
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
MINT-CITALOPRAM
Citalopram Tablets
Tablets, 10 mg, 20 mg and 40 mg citalopram (as citalopram
hydrobromide), Oral
USP
Antidepressant
Mint Pharmaceuticals Inc.
Date of Initial Authorization:
6575 Davand Drive
September 5, 2014
Mississauga, Ontario
L5T 2M3
Date of Revision:
February 28, 2024
SUBMISSION CONTROL NUMBER: 279156
Page 2 of 45
_MINT-CITALOPRAM Product Monograph_
RECENT MAJOR LABEL CHANGES
3 SERIOUS WARNINGS AND PRECAUTIONS BOX
02/2024
7 WARNINGS AND PRECAUTIONS, Hematologic
07/2022
7 WARNINGS AND PRECAUTIONS, Reproductive Health:
Female and Male Potential
07/2022
7 WARNINGS AND PRECAUTIONS, 7.1.1 Pregnant Women
07/2022
TABLE OF CONTENTS
Sections or subsections that are not applicable at the time of
authorization are not listed.
RECENT MAJOR LABEL CHANGES .......................................................................................................
2
TABLE OF CONTENTS
.......................................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................................
4
1
INDICATIONS
..............................................................................................................................
….4
1.1 Pediatrics
........................................................................................................................
4
1.2 Geriatrics
........................................................................................................................
4
2
CONTRAINDICATIONS
....................................................................................................................
5
3
SERIOUS WARNINGS AND PRECAUTIONS
..................................................................................
5
4
DOSAGE AND ADMINISTRATION
.............................................................................................